Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis

Therapeutic Advances in Respiratory Disease

Volumn 7, Issue 5, 2013, Pages 272-287

  Justo, Julie Ann ^a   Danziger, Larry H ^a   Gotfried, Mark H ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Pulmonary Associates   (United States)

Author keywords

bronchiectasis; ciprofloxacin; inhalation administration

Indexed keywords

BRONCHIECTASIS; CIPROFLOXACIN; INHALATION ADMINISTRATION;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; HUMANS; TREATMENT OUTCOME;

BETAINE; CIPROFLOXACIN; LIPOQUIN; PULMAQUIN; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BRONCHIECTASIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG HALF LIFE; DRUG PACKAGING; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; HUMAN; LUNG INFECTION; MAINTENANCE THERAPY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NON CYSTIC FIBROSIS BRONCHIECTASIS; NONHUMAN; PATHOGENESIS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STEADY STATE;

EID: 84884555861     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465813487412     Document Type: Article

References (77)

1. Alder J. Hampel B. Reimnitz P. Wilson R. (2012) Correlation of bacterial species and density at baseline to exacerbations requiring antibiotic treatment in a phase 2 trial of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) compared with placebo in patients with non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 185: A6099.
2. Ambrose P. Bhavnani S. Rubino C. Louie A. Gumbo T. Forrest A. (2007) Pharmacokinetics–pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44: 78–86.
3. Aradigm Corporation (2012) Aradigm receives U.S. FDA clearance for phase 3 clinical trial of Pulmaquin™ in patients with non-cystic fibrosis bronchiectasis (News Release). Available at: http://investor.aradigm.com/releasedetail.cfm?ReleaseID=656453 ( accessed 24 August 2012).
4. Barker A. Couch L. Fiel S. Gotfried M. Ilowite J. Meyer K. (2000) Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 162: 481–485.
5. Baydarian M. Walter R. (2008) Bronchiectasis: introduction, etiology, and clinical features. Dis Mon 54: 516–526.
6. Bayer Healthcare Pharmaceuticals (2009) Cipro tablets, Cipro oral suspension (Package Insert). Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.
7. Bayer Healthcare Pharmaceuticals (2011) Cipro I.V. (Package Insert). Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.
8. Bayer Healthcare Pharmaceuticals (2012) Start of global clinical phase III programme RESPIRE for ciprofloxacin dry powder for inhalation (DPI) (News Release). Available at: http://press.healthcare.bayer.com/en/press/news-details-page.php/14684/2012-0362 ( accessed 24 August 2012).
9. Bilton D. Bruinenberg P. Otulana B. Morishige R. Blanchard J. De Soyza A. (2009a) Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in CF and Non–CF Bronchiectasis. Am J Respir Crit Care Med 179: A3214.
10. Bilton D. De Soyza A. Haworth C. Bruinenberg P. Otulana B. (2009b) Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Eur Respir J 34(Suppl. 53): 1362s.
11. Bilton D. De Soyza A. Hayward C. Bruinenberg P. (2010) Effect of a 28-day course of two different doses of once a day liposomal ciprofloxacin for inhalation on sputum Pseudomonas aeruginosa density in non-CF bronchiectasis. Am J Respir Crit Care Med 181: A3191.
12. Bilton D. Serisier D. De Soyza A. Wolfe R. Bruinenberg P. (2011) Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of Pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis. Eur Respir J 38(Suppl. 55): 1925s.
13. Bruinenberg P. Otulana B. Blanchard J. Morishige R. Cipolla D. Wilson J. (2008) The effect of once-a-day inhaled liposomal ciprofloxacin hydrochloride on sputum bacterial density in cystic fibrosis patients with chronic pulmonary P. aeruginosa colonization. Pediatr Pulmonol 43(Suppl. 31): 401.
14. Bruinenberg P. Serisier D. Blanchard J. Cipolla D. Gonda I. (2010a) Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis. Eur Respir J 36(Suppl. 54): 5574s.
15. Bruinenberg P. Serisier D. Cipolla D. Blanchard J. (2010b) Safety, tolerability and pharmacokinetics of novel liposomal ciprofloxacin formulations for inhalation in healthy volunteers and non-cystic bronchiectasis patients. Am J Respir Crit Care Med 181: A3192.
16. Bruinenberg P. Wilson J. Serisier D. Otulana B. Blanchard J. (2009) Pharmacokinetics and antibacterial activity of inhaled liposomal ciprofloxacin hydrochloride in healthy volunteers and in cystic fibrosis (CF) patients. Eur Respir J 34(Suppl. 53): 1625s.
17. Chang A. Bell S. Byrnes C. Grimwood K. Holmes P. King P. (2010) Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand. Med J Aust 193: 356–365.
18. Chang A. Marsh R. Smith-Vaughan H. Hoffman L. (2012) Emerging drugs for bronchiectasis. Expert Opin Emerg Drugs 17: 361–378.
19. Chono S. Tanino T. Seki T. Morimoto K. (2007) Pharmacokinetic and pharmacodynamic efficacy of intrapulmonary administration of ciprofloxacin for the treatment of respiratory infections. Drug Metab Pharmacokinet 22(2): 88–95.
20. Chono S. Tanino T. Seki T. Morimoto K. (2008) Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects. Drug Dev Ind Pharm 34: 1090–1096.
21. Clinical and Laboratory Standards Institute (2012) Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute.
22. Cole P. (1986) Inflammation: a two-edged sword ’ the model of bronchiectasis. Eur J Respir Dis Suppl 147: 6–15.
23. Craig W. (1998) Pharmacokinetic-pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1–10.
24. Cystic Fibrosis Foundation (2011) Frequently asked questions. Available at: http://www.cff.org/AboutCF/Faqs/ ( accessed 7 September 2012).
25. Dal Negro R. Micheletto C. Tognella S. Visconti M. Turati C. (2008) Tobramycin nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv Ther 25: 1019–1030.
26. Danziger L. (1986) Controversies in antimicrobial therapy: innovative methods of administration. Am J Hosp Pharm 43: 646–652.
27. Davies B. Maesen F. Baur C. (1986) Ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis. Eur J Clin Microbiol 5: 226–231.
28. Dorkin H. Criollo M. Reimnitz P. Alder J. Hampel B. (2011) Randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of inhaled ciprofloxacin compared with placebo in patients with cystic fibrosis - a phase IIb study of ciprofloxacin dry powder for inhalation (DPI). Pediatr Pulmonol 46(Suppl. 34): 235.
29. Endermann R. Pickbrenner A. (2008) Pseudomonas aeruginosa chronic lung infection model; therapeutic efficacy of ciprofloxacin-betaine after two treatment cycles. In: 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 19–22 April 2008, Abstract P1920.
30. European Committee on Antimicrobial Susceptibility Testing (2012) European committee on antimicrobial susceptibility testing: breakpoint tables for interpretation of MICs and zone diameters, version 2.0. Available at: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_2.0_120221.pdf ( accessed 8 September 2012).
31. European Medicines Agency (2011) Tobi Podhaler (EPAR Product Information).
32. European Medicines Agency (2012) Colobreathe (EPAR Product Information).
33. Feldman C. (2011) Bronchiectasis: new approaches to diagnosis and management. Clin Chest Med 32: 535–546.
34. Flume P. Klepser M. (2002) The rationale for aerosolized antibiotics. Pharmacotherapy 22(3 Pt 2): 71S–79S.
35. Forrest A. Nix D. Ballow C. Goss T. Birmingham M. Schentag J. (1993) Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 37: 1073–1081.
36. Forest Laboratories UK Limited (2004) Colomycin (Patient Information Leaflet). Dartford, UK: Forest Laboratories UK Limited.
37. Fuschillo S. De Felice A. Balzano G. (2008) Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J 31: 396–406.
38. Gilead Sciences, Inc. (2012) Cayston (Prescribing Information). Foster City, CA: Gilead Sciences, Inc.
39. Goeminne P. Scheers H. Decraene A. Seys S. Dupont L. (2012) Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Resp Res 13: 21.
40. Gotfried M. Danziger L. Rodvold K. (2001) Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 119: 1114–1122.
41. Hoogkamp-Korstanje J. Klein S. (1986) Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 18: 407–413.
42. Kadota J. Tokimatsu I. Hiramatsu K. Morimoto T. Imai H. Suzaki Y. (2012) A randomized controlled study to investigate the safety and pharmacokinetics of multiple doses of ciprofloxacin dry powder for inhalation in japanese patients with moderate to severe COPD. Am J Respir Crit Care Med 185: A2273.
43. King P. (2009) The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis 4: 411–419.
44. King P. Holdsworth S. Freezer N. Villanueva E. Holmes P. (2007) Microbiologic follow-up study in adult bronchiectasis. Respir Med 101: 1633–1638.
45. Knezevic I. Schmidt S. Weskott G. Glenschek-Sieberth M. (2008) Pharmacodynamics of simulated ciprofloxacin sputum levels following a new dry powder inhalation therapy in an in vitro hollow fiber model. Pediatr Pulmonol 43(Suppl. 31): 283.
46. Le J. Ashley E. Neuhauser M. Brown J. Gentry C. Klepser M. (2010) Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 30: 562–584.
47. Li A. Sonnappa S. Lex C. Wong E. Zacharasiewicz A. Bush A. (2005) Non-CF bronchiectasis: does knowing the aetiology lead to changes in management? Eur Respir J 26: 8–14.
48. Martinez-Garcia M. Soler-Cataluna J. Perpina-Tordera M. Roman-Sanchez P. Soriano J. (2007) Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 132: 1565–1572.
49. McCormack J. Grayson M. (2010) Chapter 93 Ciprofloxacin. In: Grayson M. Crowe S. McCarthy J. Mills J. Mouton J. Norrby S. (eds) Kucers–: The Use of Antibiotics, 6th edn. London: Hodder Arnold, pp. 1265–1346.
50. Medicines and Healthcare Products Regulatory Agency (2011) Promixin (Public Assessment Report).
51. Metersky M. (2010) New treatment options for bronchiectasis. Ther Adv Respir Dis 4: 93–99.
52. Nicotra M. Rivera M. Dale A. Shepherd R. Carter R. (1995) Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest 108: 955–961.
53. Novartis Pharmaceuticals Corporation (2009) TOBI (Prescribing Information). East Hanover, NJ: Novartis Pharmaceuticals Corporation.
54. O–Donnell A. Swarnakar R. Yashina L. Nikolova P. Marinov R. Waghray P. (2009) A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 34(Suppl. 53): 1361.
55. Owens R. Ambrose P. (2005) Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41(Suppl. 2): S144's157.
56. Pasteur M. Bilton D. Hill A. and the British Thoracic Society Bronchiectasis non-CF Guideline Group (2010) British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65(Suppl. 1): i1–i58.
57. Pasteur M. Helliwell S. Houghton S. Webb S. Foweraker J. Coulden R. (2000) An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 162: 1277–1284.
58. Rademacher J. Welte T. (2011) Bronchiectasis–diagnosis and treatment. Dtsch Arztebl Int 108: 809–815.
59. Rayner C. Tillotson G. Cole P. Wilson R. (1994) Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 34: 149–156.
60. Reed M. Stern R. Myers C. Yamashita T. Blumer J. (1988) Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis. J Clin Pharmacol 28: 691–699.
61. Rodvold K. George J. Yoo L. (2011) Penetration of anti-infective agents into pulmonary epithelial lining fluid. Clin Pharmacokinet 50: 637–664.
62. Seitz A. Olivier K. Steiner C. Montes de Oca R. Holland S. Prevots D. (2010) Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 138: 944–949.
63. Serisier D. (2012) Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin. Drugs Today (Barc) 48: 339–351.
64. Serisier D. Bilton D. De Soyza T. Gonda I. (2012) An optimized inhaled ciprofloxacin formulation DRCFI (dual release ciprofloxacin for inhalation) enhances antibiotic lung concentrations and antimicrobial effect in non-CF bronchiectasis (Non-CF BE). Am J Respir Crit Care Med 185: A3659.
65. Serisier D. Kolbe J. Greville H. Gonda I. Bruinenberg P. (2011a) Inhaled liposomal ciprofloxacin significantly reduces sputum Pseudomonas aeruginosa (PA) density and increases time to first exacerbation in a 168 day placebo controlled study in non-cystic fibrosis bronchiectasis (Non-CF BE). Am J Respir Crit Care Med 183: A4866.
66. Serisier D. Thompson P. Greville H. Kolbe J. Bruinenberg P. (2011b) Dual release ciprofloxacin for inhalation (DRCFI) reduces sputum Pseudomonas aeruginosa (Pa) density and delays time to infective pulmonary exacerbation in non-cystic fibrosis (CF) Bronchiectasis (BE). Eur Respir J 38(Suppl. 55): 1928s.
67. Smith M. White L. Bowyer H. Willis J. Hodson M. Batten J. (1986) Pharmacokinetics and sputum penetration of ciprofloxacin in patients with cystic fibrosis. Antimicrob Agents Chemother 30: 614–616.
68. Stass H. Baumann-Noss S. Delesen H. Nagelschmitz J. Willman S. Edginton A. (2008a) Ciprofloxacin Pulmosphere inhalational powder: a healthy volunteer research study. In: American Thoracic Society International Conference, Toronto, Canada, 16–21 May 2008 [poster].
69. Stass H. Baumann-Noss S. Delesen H. Nagelschmitz J. Willmann S. Edginton A. (2008b) Pharmacokinetics of ciprofloxacin PulmoSphere® inhalational powder. J Cyst Fibros 7(Suppl. 2): S26, Abstract A103.
70. Stass H. Ludwig M. Nagelschmitz J. Staab D. (2008c) Safety and pharmacokinetics of inhaled dry powder ciprofloxacin after single and multiple inhalations in patients with cystic fibrosis. Pediatr Pulmonol 43(Suppl. 31): 282.
71. Stass H. Nagelschmitz J. Posselt H. (2009) Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in adolescent patients with CF. Pediatr Pulmonol 44(Suppl. 32): 258.
72. Stass H. Nagelschmitz J. Watz H. Kirsten A. (2012) Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD. In: The 2012 European Respiratory Society Annual Congress, Vienna, Austria, 1–5 September 2012, Abstract 2817.
73. Stass H. Nagelschmitz J. Weimann B. Timmer W. (2011) Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder for inhalation in patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 183: A3730.
74. Tokimatsu I. Hiramatsu K. Morimoto T. Imai H. Suzaki Y. Stass H. (2011) Safety, tolerability, and pharmacokinetics of a single dose of ciprofloxacin dry powder for inhalation (ciprofloxacin DPI) in Japanese patients with mild to moderate chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 183: A3105.
75. Weycker D. Edelsberg J. Oster G. Tino G. (2005) Prevalence and economic burden of bronchiectasis. Clin Pulm Med 12: 205–209.
76. Wilson C. Jones P. O–Leary C. Hansell D. Cole P. Wilson R. (1997) Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 10: 1754–1760.
77. Wilson R. Welte T. Polverino E. Soyza A. Greville H. O–Donnell A. (2012) Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J [ePub ahead of print].